FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3081333907> ?p ?o ?g. }

• W3081333907 endingPage "83" @default.
• W3081333907 startingPage "73" @default.
• W3081333907 abstract "Background: A newer trend has been seen recently to reuse the conventional drugs with distinct indications for the newer applications to speed up the drug discovery and development based on earlier records and safety data. Most of the non-cancerous agents could afford a little or tolerable side effects in individuals. However, the repositioning of these non-cancerous agents for successful anticancer therapy is an outstanding strategy for future anti-cancer drug development. Since more diverse and selective cancer drug targets are being discovered and developed, the approved drug collections are particularly useful to quickly identify clinically advanced anticancer drugs against those targets. Objective: Antihelminthic drugs such as Mebendazole and Albendazole (Benzimidazole class) have been reported to exhibit cytotoxicity (or anticancer activities) against several types of cancer. Therefore, this study aims to repurpose the benzimidazole scaffold for breast cancer treatment. Methods: In the present study, three hydrazone analogs having a benzimidazole motif in their structural frame were synthesized. Their in-silico binding studies against HER2 receptor (PDB ID: 4LQM) and ADMET studies were carried out using Accelrys drug discovery studio 4.1. Cytotoxicity of the synthesized compounds against HER2 overexpressed MCF-7 cell lines was determined by MTT assay. Results: One of the compounds 2-[2-(2,4-dinitrophenyl)hydrazinylidene]-2,3-dihydro-1H-benzimidazole (U1) has shown good cytotoxicity when compared to the standard Lapatinib, which is a well known HER2 inhibitor. Conclusion: Thus, the designed benzimidazole scaffold might serve as the best leads for treating breast cancer, which is additionally confirmed by performing their docking study via Accelrys discovery studio." @default.
• W3081333907 created "2020-09-01" @default.
• W3081333907 creator A5001159754 @default.
• W3081333907 creator A5022238647 @default.
• W3081333907 creator A5029439438 @default.
• W3081333907 creator A5078602007 @default.
• W3081333907 creator A5079543184 @default.
• W3081333907 creator A5089798753 @default.
• W3081333907 date "2021-04-12" @default.
• W3081333907 modified "2023-10-17" @default.
• W3081333907 title "Repurposing of Benzimidazole Scaffolds for HER2 Positive Breast Cancer Therapy: An In-Silico Approach" @default.
• W3081333907 cites W1966959008 @default.
• W3081333907 cites W1967620263 @default.
• W3081333907 cites W1973514430 @default.
• W3081333907 cites W1980671878 @default.
• W3081333907 cites W1984308718 @default.
• W3081333907 cites W1997285329 @default.
• W3081333907 cites W1997952190 @default.
• W3081333907 cites W2004142483 @default.
• W3081333907 cites W2028337996 @default.
• W3081333907 cites W2049104477 @default.
• W3081333907 cites W2065805041 @default.
• W3081333907 cites W2089330719 @default.
• W3081333907 cites W2107755135 @default.
• W3081333907 cites W2112284988 @default.
• W3081333907 cites W2116931094 @default.
• W3081333907 cites W2120343885 @default.
• W3081333907 cites W2123845161 @default.
• W3081333907 cites W2137228442 @default.
• W3081333907 cites W2141393790 @default.
• W3081333907 cites W2148881504 @default.
• W3081333907 cites W2160462349 @default.
• W3081333907 cites W2168508406 @default.
• W3081333907 cites W2171530299 @default.
• W3081333907 cites W2317841422 @default.
• W3081333907 cites W2318605753 @default.
• W3081333907 cites W2320841803 @default.
• W3081333907 cites W2338729940 @default.
• W3081333907 cites W2587570369 @default.
• W3081333907 cites W2601070101 @default.
• W3081333907 cites W2799457384 @default.
• W3081333907 cites W2806922111 @default.
• W3081333907 cites W2887766329 @default.
• W3081333907 doi "https://doi.org/10.2174/2589977512999200821170221" @default.
• W3081333907 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32955008" @default.
• W3081333907 hasPublicationYear "2021" @default.
• W3081333907 type Work @default.
• W3081333907 sameAs 3081333907 @default.
• W3081333907 citedByCount "7" @default.
• W3081333907 countsByYear W30813339072021 @default.
• W3081333907 countsByYear W30813339072022 @default.
• W3081333907 countsByYear W30813339072023 @default.
• W3081333907 crossrefType "journal-article" @default.
• W3081333907 hasAuthorship W3081333907A5001159754 @default.
• W3081333907 hasAuthorship W3081333907A5022238647 @default.
• W3081333907 hasAuthorship W3081333907A5029439438 @default.
• W3081333907 hasAuthorship W3081333907A5078602007 @default.
• W3081333907 hasAuthorship W3081333907A5079543184 @default.
• W3081333907 hasAuthorship W3081333907A5089798753 @default.
• W3081333907 hasConcept C103637391 @default.
• W3081333907 hasConcept C104317684 @default.
• W3081333907 hasConcept C109316439 @default.
• W3081333907 hasConcept C121608353 @default.
• W3081333907 hasConcept C126322002 @default.
• W3081333907 hasConcept C178790620 @default.
• W3081333907 hasConcept C185592680 @default.
• W3081333907 hasConcept C202751555 @default.
• W3081333907 hasConcept C2775905019 @default.
• W3081333907 hasConcept C2777292972 @default.
• W3081333907 hasConcept C2777329042 @default.
• W3081333907 hasConcept C2778484023 @default.
• W3081333907 hasConcept C2779786085 @default.
• W3081333907 hasConcept C2780035454 @default.
• W3081333907 hasConcept C530470458 @default.
• W3081333907 hasConcept C55493867 @default.
• W3081333907 hasConcept C70721500 @default.
• W3081333907 hasConcept C71924100 @default.
• W3081333907 hasConcept C74187038 @default.
• W3081333907 hasConcept C86803240 @default.
• W3081333907 hasConcept C98274493 @default.
• W3081333907 hasConceptScore W3081333907C103637391 @default.
• W3081333907 hasConceptScore W3081333907C104317684 @default.
• W3081333907 hasConceptScore W3081333907C109316439 @default.
• W3081333907 hasConceptScore W3081333907C121608353 @default.
• W3081333907 hasConceptScore W3081333907C126322002 @default.
• W3081333907 hasConceptScore W3081333907C178790620 @default.
• W3081333907 hasConceptScore W3081333907C185592680 @default.
• W3081333907 hasConceptScore W3081333907C202751555 @default.
• W3081333907 hasConceptScore W3081333907C2775905019 @default.
• W3081333907 hasConceptScore W3081333907C2777292972 @default.
• W3081333907 hasConceptScore W3081333907C2777329042 @default.
• W3081333907 hasConceptScore W3081333907C2778484023 @default.
• W3081333907 hasConceptScore W3081333907C2779786085 @default.
• W3081333907 hasConceptScore W3081333907C2780035454 @default.
• W3081333907 hasConceptScore W3081333907C530470458 @default.
• W3081333907 hasConceptScore W3081333907C55493867 @default.
• W3081333907 hasConceptScore W3081333907C70721500 @default.
• W3081333907 hasConceptScore W3081333907C71924100 @default.

• next